Bernstein: Why AstraZeneca’s biggest growth opportunity is being overlooked

Bernstein reiterated an outperform rating on AstraZeneca with a £186 price target, about 37% above the £135.54 close, implying meaningful upside. The broker’s 2030 revenue forecast of $89.06 billion is 11% above AstraZeneca guidance and 8% above consensus, with the largest gap in Wainua at $4.80 billion versus $1.80 billion consensus by 2035. Bernstein also sees upside in AZD0780, tozorakimab, and the approved portfolio, but the article remains fundamentally a bullish analyst note rather than a company catalyst.

Analysis

The market is still treating AZN like a mature oncology story with a modest pipeline kicker, but the embedded option value is increasingly in non-oncology where commercial penetration is likely to be constrained more by diagnosis, sequencing, and physician habit than by molecule quality. That creates a delayed-revenue convexity profile: the stock can stay under-owned until phase 3 readouts and real-world utilization data force upward revisions, then rerate quickly as the sell-side starts capitalizing peak-sales durability instead of just near-term approvals.

The most important second-order effect is competitive timing. If AZD0780 avoids fasting and is easier to combine, it can win not just on efficacy but on adherence and prescribing friction, which matters in primary-care-adjacent chronic disease markets where small workflow advantages translate into large share. That same dynamic pressures incumbents and late entrants to spend more on payer access and education, compressing margins even if the class expands; the first mover may gain share disproportionately if the market underestimates convenience as a moat.

The contrarian read is that the consensus gap is not primarily about blockbuster probability, but about the denominator: modest diagnosis rates and slow care-path conversion mean the market is undercounting how much demand can inflect once screening improves. For Wainua specifically, the real catalyst is not the drug itself but the U.S. ATTR pipeline rate; moving diagnosis from roughly one-third toward even mid-40s would mechanically lift treatable population estimates and force multi-year forecast upgrades. That makes the next 12-24 months more about data and access than about clinical surprise, and the stock could grind higher before the H2 2026 readout if channel checks start showing accelerating scripts.

Key Decisions for Investors

• Go long AZN versus a European pharma basket over a 6-12 month horizon: the market is underpricing non-oncology earnings power, and the setup offers asymmetric upside if diagnosis/access trends improve; risk is a 10-15% derating if late-stage data or reimbursement disappoint.
• Buy AZN 12-18 month call spreads rather than stock for the H2 2026 catalyst window: this captures rerating potential while limiting downside if phase 3 timing slips or consensus remains skeptical longer than expected.
• Pair trade: long AZN / short a mature large-cap pharma peer with weaker pipeline convexity over the next 2-4 quarters; the thesis is multiple expansion for underappreciated growth, not a sector-wide beta call.
• If willing to express a secondary beneficiary, initiate a small long in diagnostics or specialty testing exposure tied to ATTR awareness over the next 12 months; the thesis is that higher diagnosis rates are the real bottleneck and the first-order beneficiary of better screening may be upstream of AZN.